Yourgene Health logo

YGEN - Yourgene Health Share Price

11.75p 0.1  1.1%

Last Trade - 22/10/19

Sector
Healthcare
Size
Small Cap
Market Cap £69.6m
Enterprise Value £68.7m
Revenue £8.88m
Position in Universe 1071st / 1816
Bullish
Bearish
Unlock YGEN Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

YGEN Revenue Unlock YGEN Revenue

Net Income

YGEN Net Income Unlock YGEN Revenue

Normalised EPS

YGEN Normalised EPS Unlock YGEN Revenue

PE Ratio Range

YGEN PE Ratio Range Unlock YGEN Revenue

Dividend Yield Range

YGEN Dividend Yield Range Unlock YGEN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
YGEN EPS Forecasts Unlock YGEN Revenue
Profile Summary

Yourgene Health PLC, formerly Premaitha Health PLC, is engaged in molecular diagnostics business for research into, and the development and commercialization of gene analysis techniques for pre-natal screening and other clinical applications in the early detection, monitoring and treatment of disease. The Company's product, the IONA test is a non-invasive in vitro diagnostic product for prenatal screening enabling clinical laboratories to offer a regulated non-invasive prenatal test in-house. The IONA test estimates the risk of a fetus having Down's syndrome or other serious genetic diseases. The risks that fetus may be affected with include Trisomy 21 (Down's syndrome), Trisomy 18 (Edwards' syndrome), Trisomy 13 (Patau's syndrome) and Fetal sex determination optional. The analysis is performed on cell-free placental deoxyribonucleic acid (DNA) from a maternal blood sample, with test results available in three days turnaround time.

Directors
Last Annual March 31st, 2019
Last Interim March 31st, 2019
Incorporated April 13, 2000
Public Since May 21, 2002
No. of Shareholders: n/a
No. of Employees: 94
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share ,
Exchange London Stock Exchange (Full)
Shares in Issue 1,638,639,932
Free Float (0.0%)
Eligible for
ISAs
SIPPs
YGEN Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for YGEN
Upcoming Events for YGEN
Similar to YGEN
© Stockopedia 2019, Thomson Reuters, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.